Results 21 to 30 of about 285,607 (297)

Pulmonary arterial hypertension [PDF]

Orphanet Journal of Rare Diseases, 2013
Abstract Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right heart failure and ultimately death if untreated. The first classification of PH was proposed in 1973. In 2008, the fourth World Symposium on PH held in Dana Point (California, USA) revised previous classifications.
Montani, David, Günther, Sven, Dorfmüller, Peter, Perros, Frédéric, Girerd, Barbara, Garcia, Gilles, Jaïs, Xavier, Savale, Laurent, Artaud-Macari, Elise, Price, Laura, Humbert, Marc, Simonneau, Gérald, Sitbon, Olivier   +12 more
openaire   +3 more sources

Schistosomiasis Pulmonary Arterial Hypertension [PDF]

Frontiers in Immunology, 2020
Pulmonary arterial hypertension (PAH) is a disease of the lung blood vessels that results in right heart failure. PAH is thought to occur in about 5% to 10% of patients with hepatosplenic schistosomiasis, particularly due to S. mansoni. The lung blood vessel injury may result from a combination of embolization of eggs through portocaval shunts into the
Jean Pierre Sibomana, Jean Pierre Sibomana, Aloma Campeche, Roberto J. Carvalho-Filho, Ricardo Amorim Correa, Helena Duani, Virginia Pacheco Guimaraes, Joan F. Hilton, Biruk Kassa, Biruk Kassa, Rahul Kumar, Rahul Kumar, Michael H. Lee, Michael H. Lee, Camila M. C. Loureiro, Sula Mazimba, Claudia Mickael, Rudolf K. F. Oliveira, Jaquelina S. Ota-Arakaki, Camila Farnese Rezende, Luciana C. S. Silva, Edford Sinkala, Hanan Yusuf Ahmed, Brian B. Graham, Brian B. Graham   +24 more
openaire   +5 more sources

Role of prostacyclin in pulmonary hypertension [PDF]

, 2014
Date of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is ...
Ali FY, Butrous G, Chester AH, Geiger LE, Newsholme SJ, Nguyen H, Ruan CH, Smith WL, Whittaker N   +8 more
core   +3 more sources

Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers

Pulmonary Circulation, 2021
Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Liza Botros, Samara M.A. Jansen, Ali Ashek, Onno A. Spruijt, Jelco Tramper, Anton Vonk Noordegraaf, Jurjan Aman, Hans Harms, Frances S. deMan, Marc C. Huisman, Lan Zhao, Harm J. Bogaard   +11 more
doaj   +1 more source

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Pulmonary Circulation, 2020
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary ...
John J. Ryan, Lana Melendres-Groves, Roham T. Zamanian, Ronald J. Oudiz, Murali Chakinala, Erika B. Rosenzweig, Mardi Gomberg-Maitland   +6 more
doaj   +1 more source

High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude

Pulmonary Circulation, 2020
While estimates of pulmonary arterial hypertension incidence and prevalence commonly range from 1–3/million and 15–25/million, respectively, clinical experience at our institution suggested much higher rates.
Jason Dubroff, Lana Melendres, Yan Lin, Daniel Raley Beene, Loren Ketai   +4 more
doaj   +1 more source

Pulmonary artery denervation for pulmonary arterial hypertension

Trends in Cardiovascular Medicine, 2021
Pulmonary arterial hypertension remains a progressive, life-limiting disease despite optimal medical therapy. Pulmonary artery denervation has arisen as a novel intervention in the treatment of pulmonary arterial hypertension, and other forms of pulmonary hypertension, with the aim of reducing the sympathetic activity of the pulmonary circulation.
Constantine, A, Dimopoulos, K
openaire   +4 more sources

Clinical implications of partial anomalous pulmonary venous connection: a rare cause of severe pulmonary arterial hypertension

Pulmonary Circulation, 2020
Isolated partial anomalous pulmonary venous connection (PAPVC) is an uncommon congenital heart anomaly that is sporadically associated with pulmonary arterial hypertension in the adult population.
Alex Pizzini, Thomas Sonnweber, Renate Frank, Markus Theurl, Günter Weiss, Ivan Tancevski, Judith Löffler-Ragg   +6 more
doaj   +1 more source

Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension

Journal of Cardiothoracic Surgery, 2021
Pulmonary arterial hypertension is a type of malignant pulmonary vascular disease, which is mainly caused by the increase of pulmonary vascular resistance due to the pathological changes of the pulmonary arteriole itself, which eventually leads to right ...
Jianying Deng
doaj   +1 more source

Non-invasive assessment of pulmonary vascular resistance in pulmonary hypertension: Current knowledge and future direction [PDF]

, 2017
Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised. Pulmonary hypertension is not a diagnosis in itself; it is caused by a number of differing diseases each with different treatments and prognoses.
Hills, G, Kuppusamy, H, Naing, P, Playford, D, Scalia, G   +4 more
core   +2 more sources